Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
October 23 2008 - 6:54PM
PR Newswire (US)
SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the
BIOCOM Investor Conference in San Diego on Tuesday, October 28,
2008 at 10:30 a.m. PT. Mark G. Foletta, Amylin's Senior Vice
President of Finance and Chief Financial Officer, will be providing
a corporate overview. The live presentation will be Web cast, and a
recording will be made available following the event. The Web cast
and recording will be accessible through Amylin's corporate Web
site, located at http://www.amylin.com/. To access the live Web
cast, please log on to Amylin's site approximately fifteen minutes
prior to the presentation to register and download any necessary
audio software. About Amylin Pharmaceuticals Amylin Pharmaceuticals
is a biopharmaceutical company committed to improving lives through
the discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide
acetate) injection and BYETTA(R) (exenatide) injection. Amylin's
research and development activities leverage the company's
expertise in metabolism to develop potential therapies to treat
diabetes and obesity. Amylin is headquartered in San Diego,
California with over 2,000 employees nationwide. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Michael York, Senior Director, Investor Relations of
Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024